A Phase 1 interventional study of IPG1094 300 mg SAD and IPG1094 600 mg SAD in Healthy Volunteers, sponsored by Nanjing Immunophage Biotech Co., Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of single dose orally administered IPG1094 in healthy adult participants.
Nanjing Immunophage Biotech Co., Ltd is the lead sponsor of 11 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following criteria to be included in the study:
Demography
Body weight between 50 and 100 kg (inclusive) and (BMI) within 18\~32 kg/m2 (inclusive).
Health status
In good health as determined by screening tests. Good health is defined as having no abnormalities identified by a detailed medical history, full physical examination (including measurement of blood pressure and pulse rate), 12-lead , and clinical laboratory tests.
Vital signs (measured after resting for 5 minutes seated position) within normal range, or outside the normal range and not considered clinically significant by the Investigator.
Standard 12-lead ECG parameters (recorded after resting for 5 minutes in supine position) in the following ranges; interval(QTc) (Fridericia algorithm recommended) ≤ 450 ms for males and 470 ms for females, and normal ECG tracing, or abnormal ECG tracing not considered clinically relevant by the Investigator.
Laboratory parameters demonstrating no clinically significant abnormalities, as determined by the Investigator. A total outside the normal range may be acceptable if total bilirubin does not exceed 1.5 × (ULN) conjugated bilirubin (with the exception of a participant with documented Gilbert syndrome).
Female participants must not be pregnant or breastfeeding and must use an effective method (as described in Section 4.5.4), with the exception of participants who have undergone sterilization in the preceding 3 months, or who are .
A woman of (WOCBP) must undergo pregnancy testing prior to the first dose of the Medicinal Product (IMP). The participant must be excluded from the study if the serum pregnancy test is positive.
A postmenopausal state is defined as 12 months of amenorrhea without an alternative medical cause. In the absence of 12 months of amenorrhea, menopause may be confirmed by follicle stimulating hormone(FSH) measurement (> 40 IU/L or milli-International unit(mIU)/mL).Females on Hormonal Replacement therapy (HRT ), where menopausal status is indeterminate, will be required to use a non-estrogen hormonal contraceptive method if participants wish to continue their HRT during the study. Participants must otherwise discontinue HRT to allow for confirmation of postmenopausal status prior to enrollment in the study.
Regulation
Exclusion Criteria:
Participants who meet any of the following criteria will be excluded from the study:
Medical history and clinical status
Excessive consumption of beverages containing xanthine bases (defined as more than 4 glasses per day).
Interfering substances
Any vaccination in the 28 days prior to administration of the first dose.
General conditions
Any participant who is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff thereof directly involved in conducting the study or any person dependent on (employees or immediate family members) the study site, the Investigator or the Sponsor.
Biological status
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Four subjects in this cohort will receive a single dose of IPG1094 100 mg and two subjects will receive a single dose of placebo 100 mg orally.
Drug: IPG1094 100 mg SAD
Six subjects in this cohort will receive a single dose of IPG1094 300 mg and two subjects will receive a single dose of placebo 300 mg orally.
Drug: IPG1094 300 mg SAD
Six subjects in this cohort will receive a single dose of IPG1094 600 mg and two subjects will receive a single dose of placebo 600mg orally.
Drug: IPG1094 600 mg SAD
Six subjects in this cohort will receive a single dose of IPG1094 900 mg qd and two subjects will receive a single dose of placebo 900mg qd orally.
Drug: IPG1094 900 mg SAD
Six subjects in this cohort will receive a single dose of IPG1094 1200 mg and two subjects will receive a single dose of placebo 1200 mg orally.
Drug: IPG1094 1200 mg SAD
Dosing begins on Day 1 and continues for 10 days with daily doses of 600 mg QD. Subjects are discharged on Day 14, followed by a 7-day post-dosing follow-up. Six subjects in this cohort will receive IPG1094 600 mg and two subjects will receive placebo.
Drug: IPG1094 600 mg MAD QD
Dosing begins on Day 1 and continues for 10 days with twice daily 200 mg. Subjects are discharged on Day 14, followed by a 7-day post-dosing follow-up. Six subjects in this cohort will receive IPG1094 200 mg nd two subjects will receive placebo.
Drug: IPG1094 200 mg MAD BID
Dosing begins on Day 1 and continues for 10 days with twice daily 300 mg. Subjects are discharged on Day 14, followed by a 7-day post-dosing follow-up. Six subjects in this cohort will receive IPG1094 300 mg and two subjects will receive placebo.
Drug: IPG1094 300 mg MAD BID
For Cohort FE-1, Six subjects administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fasted condition, and Day 5 (anticipated) of Period 2 under the fed condition. 300 mg per administration.
Drug: IPG1094 300 mg Fasted-Fed
For Cohort FE-2, Six subjects administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fed condition, and Day 5 (anticipated) of Period 2 under fasted condition. 300 mg per administration.
Drug: IPG1094 300 mg Fed-Fasted
a Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,300 mg, QD, 3 tablets
A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days, 600 mg, QD, 6tablets
A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,900 mg, QD, 9tablets
A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,1200 mg, QD, 12 tablets
Dosing begins on Day 1 and continues for 10 days with daily doses of 600 mg QD.
Dosing starts on Day 1 and extends over a 10-day period. Subjects are discharged on Day 13, with a follow-up 7 days after the last dose, each cohort comprises approximately eight subjects, with 6 subjects on IPG1094 and 2 subjects on placebo
Dosing starts on Day 1 and extends over a 10-day period. Subjects are discharged on Day 13, with a follow-up 7 days after the last dose, each cohort comprises approximately eight subjects, with 6 subjects on IPG1094 and 2 subjects on placebo
For Cohort FE-2, administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fed condition, and Day 5 (anticipated) of Period 2 under fasted condition.
For Cohort FE-1, administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fasted condition, and Day 5 (anticipated) of Period 2 under the fed condition.
a Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,100 mg, QD, 1 tablets
Adverse Events
Evaluation of adverse events
Time frame: Part A (SAD):From signed ICF up to D8;Part B (MAD):From signed ICF up to D17;Part C (MAD):From signed ICF up to D17;Part D (FE):From signed ICF up to D12;
Cmax
Maximum observed concentration Part A: at 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: at 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration.
Time frame: Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12
Tmax
Time of maximum observed concentration Part A: at 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: at 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration.
Time frame: Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12
AUC0-t
The parameter would be calculated using the linear trapezoidal rule: Linear up log down. Part A: 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration
Time frame: Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12
CL/F
Apparent clearance following extravascular administration, calculated as Dose/AUC0-inf Part A: 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration
Time frame: Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12
| Milestone | Part A :100 mg SAD | Part A : 300 mg SAD | Part A : 600 mg SAD | Part A : 900mg SAD | Part A : 1200mg SAD | Part B : 600 mg QD MAD | Part C : 200 mg BID MAD | Part C : 300 mg BID MAD | PartA: Placebo | PartB: Placebo | Part C: Placebo | Part D 300 mg Fasted-Fed | Part D 300 mg Fed-Fasted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 10 | 2 | 4 | 7 | 6 |
| Completed | 4 | 6 | 6 | 6 | 6 | 4 | 6 | 0 | 10 | 2 | 2 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 6 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 6 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
Evaluation of adverse events
| Participants | PartA: IPG1094 100 mg SAD | PartA: IPG1094 300 mg SAD | PartA: IPG1094 600 mg SAD | PartA: IPG1094 900mg SAD | PartA: IPG1094 1200mg SAD | PartB: IPG1094 600 mg MAD QD | PartC: IPG1094 200 mg MAD BID | PartC: IPG1094 300 mg MAD BID | Part D:IPG1094 300mg Fasted | PartD: IPG1094 300mg Fed | PartA: Placebo | PartB: Placebo | Part C: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Events | 0 | 2 | 3 | 3 | 6 | 6 | 6 | 6 | 5 | 7 | 5 | 2 | 2 |
Maximum observed concentration Part A: at 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: at 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration.
| ng/mL | Part A: IPG1094 100 mg SAD | Part A: IPG1094 300 mg SAD | Part A: IPG1094 600 mg SAD | Part A: IPG1094 900mg SAD | Part A: IPG1094 1200mg SAD | Part B: IPG1094 600 mg MAD QD | Part C: IPG1094 200 mg MAD BID | Part C: IPG1094 300 mg MAD BID | Part D: IPG1094 300mg Fasted | PartD: IPG1094 300mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|
| the SAD group and the single-dose administration (D1) of the MAD group and fasted &Fed status | 508 ± 262 | 2180 ± 1000 | 5500 ± 2160 | 8330 ± 3030 | 18800 ± 6250 | 4860 ± 2370 | 1400 ± 699 | 4650 ± 2480 | 2280 ± 1880 | 5630 ± 2230 |
| The Cmax data of the MAD group after multiple administrations (D10) | — | — | — | — | — | 15800 ± 17500 | 8830 ± 2860 | — | — | — |
Time of maximum observed concentration Part A: at 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: at 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration.
| h | Part A: IPG1094 100 mg SAD | Part A: IPG1094 300 mg SAD | Part A: IPG1094 600 mg SAD | Part A: IPG1094 900mg SAD | Part A: IPG1094 1200mg SAD | Part B: IPG1094 600 mg MAD QD | Part C: IPG1094 200 mg MAD BID | Part C: IPG1094 300 mg MAD BID | PartD: IPG1094 300mg Fasted | PartD: IPG1094 300mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|
| the SAD group and the single-dose administration (D1) of the MAD group and fasted &Fed status | 3.19 (2.52 to 5.7) | 2.55 (2.42 to 3.92) | 5.91 (2.45 to 6.00) | 2.98 (2.45 to 9.00) | 7.49 (4.00 to 9.00) | 3.04 (2.43 to 3.92) | 2.03 (1.15 to 4.2) | 3.98 (3.00 to 4.00) | 4.36 (1.42 to 12.07) | 4.81 (1.97 to 9.00) |
| The Tmax data of the MAD group after multiple administrations (D10) | — | — | — | — | — | 2.72 (2.3 to 6.28) | 1.43 (0.92 to 6.03) | — | — | — |
The parameter would be calculated using the linear trapezoidal rule: Linear up log down. Part A: 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration
| h*ng/mL | Part A:IPG1094 100 mg SAD | PartA:IPG1094 300 mg SAD | Part A:IPG1094 600 mg SAD | Part A:IPG1094 900mg SAD | PartA:IPG1094 1200mg SAD | Part B:IPG1094 600 mg MAD QD | Part C:IPG1094 200 mg MAD BID | PartC:IPG1094 300 mg MAD BID | Part D: IPG1094 300 mg Fasted | PartD: IPG1094 300mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|
| the SAD group and the single-dose administration (D1) of the MAD group and fasted &Fed status | 5950 ± 1520 | 26100 ± 14100 | 85600 ± 40200 | 157000 ± 93400 | 345000 ± 151000 | 55200 ± 36900 | 8500 ± 5630 | 28900 ± 16700 | 29700 ± 37100 | 48800 ± 30900 |
| the MAD group after multiple administrations (D10) | — | — | — | — | — | 195000 ± 239000 | 63000 ± 25500 | — | — | — |
Apparent clearance following extravascular administration, calculated as Dose/AUC0-inf Part A: 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration
| L/h | Part A:IPG1094 100 mg SAD | Part A: IPG1094 300 mg SAD | Part A: IPG1094 600 mg SAD | Part A: IPG1094 900mg SAD | Part A: IPG1094 1200mg SAD | Part B: IPG1094 600 mg MAD QD | Part C: IPG1094 200 mg MAD BID | Part C: IPG1094 300 mg MAD BID | Part D: IPG1094 300 mg Fasted | PartD: IPG1094 300mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|
| the SAD group and the single-dose administration (D1) of the MAD group and fasted &Fed status | 14.8 ± 3.73 | 13.7 ± 7.62 | 9.07 ± 5.94 | 8.45 ± 6.18 | 4.21 ± 2.15 | — | — | — | — | — |
| the MAD group after multiple administrations (D10) | — | — | — | — | — | 7.44 ± 5.59 | 3.68 ± 1.64 | — | — | — |
Collected over Part A (SAD):From signed ICF up to D8;Part B (MAD):From signed ICF up to D17;Part C (MAD):From signed ICF up to D17;Part D (FE):From signed ICF up to D12;. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IPG1094 100 mg SAD | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| IPG1094 300 mg SAD | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| IPG1094 600 mg SAD | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| IPG1094 900mg SAD | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| IPG1094 1200mg SAD | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| IPG1094 600 mg MAD QD | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| IPG1094 200 mg MAD BID | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| IPG1094 300 mg MAD BID | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part D:Fasted | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Part D: Fed | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| PartA: Placebo | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| PartB: Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Part C: Placebo | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Event | IPG1094 100 mg SAD | IPG1094 300 mg SAD | IPG1094 600 mg SAD | IPG1094 900mg SAD | IPG1094 1200mg SAD | IPG1094 600 mg MAD QD | IPG1094 200 mg MAD BID | IPG1094 300 mg MAD BID | Part D:Fasted | Part D: Fed | PartA: Placebo | PartB: Placebo | Part C: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nervous system disordersNervous system disorders | 0/4 | 1/6 | 2/6 | 2/6 | 6/6 | 6/6 | 5/6 | 6/6 | 4/12 | 5/12 | 1/10 | 2/2 | 2/4 |
| Gastrointestinal disordersGastrointestinal disorders | 0/4 | 0/6 | 2/6 | 0/6 | 4/6 | 3/6 | 2/6 | 5/6 | 0/12 | 0/12 | 0/10 | 1/2 | 1/4 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 0/4 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 2/6 | 2/6 | 0/12 | 1/12 | 0/10 | 0/2 | 0/4 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 0/4 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/12 | 0/12 | 3/10 | 0/2 | 0/4 |
| General disorders and administration site conditionsGeneral disorders | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/12 | 1/12 | 1/10 | 0/2 | 1/4 |
| Infections and infestationsInfections and infestations | 0/4 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 1/12 | 1/10 | 0/2 | 0/4 |
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 0/4 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/12 | 0/12 | 0/10 | 0/2 | 0/4 |
| InvestigationsInvestigations | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 1/12 | 1/12 | 0/10 | 0/2 | 0/4 |
| Age, Categorical(Participants) | IPG1094 300 mg SAD | IPG1094 100 mg SAD | IPG1094 600 mg SAD | IPG1094 900mg SAD | IPG1094 1200mg SAD | IPG1094 600 mg MAD QD | IPG1094 200 mg MAD BID | IPG1094 300 mg MAD BID | PartA: Placebo | PartB: Placebo | Part C: Placebo | Part D IPG1094 300 mg Fasted-Fed | Part D IPG1094 300 mg Fed-Fasted | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 4 | 6 | 6 | 6 | 6 | 7 | 6 | 10 | 2 | 4 | 7 | 6 | 76 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | IPG1094 300 mg SAD | IPG1094 100 mg SAD | IPG1094 600 mg SAD | IPG1094 900mg SAD | IPG1094 1200mg SAD | IPG1094 600 mg MAD QD | IPG1094 200 mg MAD BID | IPG1094 300 mg MAD BID | PartA: Placebo | PartB: Placebo | Part C: Placebo | Part D IPG1094 300 mg Fasted-Fed | Part D IPG1094 300 mg Fed-Fasted | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 30.0 ± 9.59 | 27.3 ± 5.25 | 29.3 ± 6.28 | 28.7 ± 5.01 | 26.3 ± 3.14 | 32.3 ± 4.55 | 29.4 ± 5.44 | 31.0 ± 9.53 | 27.8 ± 5.27 | 33.5 ± 6.36 | 27.5 ± 4.65 | 30.1 ± 5.18 | 30.2 ± 1.72 | 29.6 ± 5.79 |
| Sex: Female, Male(Participants) | IPG1094 300 mg SAD | IPG1094 100 mg SAD | IPG1094 600 mg SAD | IPG1094 900mg SAD | IPG1094 1200mg SAD | IPG1094 600 mg MAD QD | IPG1094 200 mg MAD BID | IPG1094 300 mg MAD BID | PartA: Placebo | PartB: Placebo | Part C: Placebo | Part D IPG1094 300 mg Fasted-Fed | Part D IPG1094 300 mg Fed-Fasted | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 4 | 4 | 2 | 4 | 3 | 2 | 4 | 1 | 0 | 2 | 3 | 35 |
| Male | 3 | 1 | 2 | 2 | 4 | 2 | 4 | 4 | 6 | 1 | 4 | 5 | 3 | 41 |
| Race (NIH/OMB)(Participants) | IPG1094 300 mg SAD | IPG1094 100 mg SAD | IPG1094 600 mg SAD | IPG1094 900mg SAD | IPG1094 1200mg SAD | IPG1094 600 mg MAD QD | IPG1094 200 mg MAD BID | IPG1094 300 mg MAD BID | PartA: Placebo | PartB: Placebo | Part C: Placebo | Part D IPG1094 300 mg Fasted-Fed | Part D IPG1094 300 mg Fed-Fasted | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Asian | 3 | 1 | 2 | 2 | 3 | 2 | 1 | 3 | 0 | 0 | 1 | 1 | 0 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 3 | 2 | 2 | 4 | 3 | 3 | 5 | 3 | 10 | 2 | 3 | 6 | 5 | 51 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Ethnicity (NIH/OMB)(Participants) | IPG1094 300 mg SAD | IPG1094 100 mg SAD | IPG1094 600 mg SAD | IPG1094 900mg SAD | IPG1094 1200mg SAD | IPG1094 600 mg MAD QD | IPG1094 200 mg MAD BID | IPG1094 300 mg MAD BID | PartA: Placebo | PartB: Placebo | Part C: Placebo | Part D IPG1094 300 mg Fasted-Fed | Part D IPG1094 300 mg Fed-Fasted | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 2 | 2 | 1 | 2 | 1 | 15 |
| Not Hispanic or Latino | 6 | 3 | 5 | 6 | 6 | 4 | 5 | 5 | 8 | 0 | 3 | 5 | 5 | 61 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BMI(kg/m²) | IPG1094 300 mg SAD | IPG1094 100 mg SAD | IPG1094 600 mg SAD | IPG1094 900mg SAD | IPG1094 1200mg SAD | IPG1094 600 mg MAD QD | IPG1094 200 mg MAD BID | IPG1094 300 mg MAD BID | PartA: Placebo | PartB: Placebo | Part C: Placebo | Part D IPG1094 300 mg Fasted-Fed | Part D IPG1094 300 mg Fed-Fasted | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 24.2 ± 3.105 | 24.45 ± 3.515 | 23.07 ± 1.969 | 27.88 ± 2.169 | 23.02 ± 3.043 | 25.88 ± 3.274 | 26.26 ± 2.985 | 24.88 ± 2.841 | 25.09 ± 3.446 | 23.1 ± 0.566 | 25.23 ± 2.311 | 24.67 ± 2.969 | 23.32 ± 1.426 | 24.63 ± 3.198 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Jul 2022, 9 months.
Results were first posted in May 2026, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MIF Inhibitor IPG1094
Nanjing Immunophage Biotech Co., Ltd